NASDAQ · ORGO

Organogenesis Holdings Inc.

$2.55 +$0.16 (+6.69%) 1D After hours

Key Metrics

$307.53M
Market cap
113.10×
P/E · TTM
$514.70M
Revenue · TTM
$2.72M
Net income
EPS · TTM $0.02
Dividend yield
Free cash flow $17.08M
Beta · 1Y 1.62
EBITDA · TTM $20.28M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 13
    The stock moved +12.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 13
  • Apr 2
    From its Feb 2 high, the share price fell 47%.

    Peak close $4.23 on Feb 2; trough close $2.24 on Apr 2. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -47%
  • Feb 27
    The stock moved -13.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 27

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$307.53M
Enterprise value
Shares outstanding128.7M
52-wk range$2.04 – $7.08
Avg volume · 20D1.1M
Net cash
Book value / share$1.94
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Organogenesis Holdings Inc.
IPO dateNov 29, 2016
Employees854

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E113.10
P/S0.60
P/FCF18.00
EV/EBITDA
EV/Sales
Graham №$0.97

Profitability

Gross
Operating 0.8%
Net 0.5%
FCF 3.3%
ROE / ROIC 1.1% · 1.8%

Financial Health

Current ratio3.53
Quick ratio3.16
Debt / equity
Debt / EBITDA
Net cash
Working capital$192.48M

Cash Flow · TTM

Operating CF $30.75M
Capex −$13.67M
Free cash flow $17.08M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

2.6
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

$0.97 vs $2.55
Trades 2.6× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings